Global Neuromyelitis Optica Drug Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Page: 104

Published Date: 18 Mar 2023

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Related Reports
Product Tags

Description

Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.

Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.

According to our (Global Info Research) latest study, the global Neuromyelitis Optica Drug market size was valued at USD 48 million in 2022 and is forecast to a readjusted size of USD 59 million by 2029 with a CAGR of 2.9% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

Europe is the largest Neuromyelitis Optica Drug market with about 40% market share. North America is follower, accounting for about 35% market share.

The key players are Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP etc. Top 3 companies occupied about 35% market share.

This report is a detailed and comprehensive analysis for global Neuromyelitis Optica Drug market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:
Global Neuromyelitis Optica Drug market size and forecasts, in consumption value ($ Million), 2018-2029
Global Neuromyelitis Optica Drug market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Neuromyelitis Optica Drug market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Neuromyelitis Optica Drug market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Neuromyelitis Optica Drug
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Neuromyelitis Optica Drug market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, Fresenius, Teva, Sandoz and Intas, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market segmentation
Neuromyelitis Optica Drug market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
    Glucocorticoids
    Immunotherapies
    Others

Market segment by Application
    Acute Attack
    Remission Prophylactic Treatment

Market segment by players, this report covers
    Pfizer
    Fresenius
    Teva
    Sandoz
    Intas
    Gyjtrs
    NANG KUANG
    Tianjin Kingyork
    Baxter
    CSL
    Grifols
    Octapharma
    CBOP

Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
    South America (Brazil, Argentina and Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Neuromyelitis Optica Drug product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Neuromyelitis Optica Drug, with revenue, gross margin and global market share of Neuromyelitis Optica Drug from 2018 to 2023.
Chapter 3, the Neuromyelitis Optica Drug competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Neuromyelitis Optica Drug market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Neuromyelitis Optica Drug.
Chapter 13, to describe Neuromyelitis Optica Drug research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Neuromyelitis Optica Drug
    1.2 Market Estimation Caveats and Base Year
    1.3 Classification of Neuromyelitis Optica Drug by Type
        1.3.1 Overview: Global Neuromyelitis Optica Drug Market Size by Type: 2018 Versus 2022 Versus 2029
        1.3.2 Global Neuromyelitis Optica Drug Consumption Value Market Share by Type in 2022
        1.3.3 Glucocorticoids
        1.3.4 Immunotherapies
        1.3.5 Others
    1.4 Global Neuromyelitis Optica Drug Market by Application
        1.4.1 Overview: Global Neuromyelitis Optica Drug Market Size by Application: 2018 Versus 2022 Versus 2029
        1.4.2 Acute Attack
        1.4.3 Remission Prophylactic Treatment
    1.5 Global Neuromyelitis Optica Drug Market Size & Forecast
    1.6 Global Neuromyelitis Optica Drug Market Size and Forecast by Region
        1.6.1 Global Neuromyelitis Optica Drug Market Size by Region: 2018 VS 2022 VS 2029
        1.6.2 Global Neuromyelitis Optica Drug Market Size by Region, (2018-2029)
        1.6.3 North America Neuromyelitis Optica Drug Market Size and Prospect (2018-2029)
        1.6.4 Europe Neuromyelitis Optica Drug Market Size and Prospect (2018-2029)
        1.6.5 Asia-Pacific Neuromyelitis Optica Drug Market Size and Prospect (2018-2029)
        1.6.6 South America Neuromyelitis Optica Drug Market Size and Prospect (2018-2029)
        1.6.7 Middle East and Africa Neuromyelitis Optica Drug Market Size and Prospect (2018-2029)

2 Company Profiles
    2.1 Pfizer
        2.1.1 Pfizer Details
        2.1.2 Pfizer Major Business
        2.1.3 Pfizer Neuromyelitis Optica Drug Product and Solutions
        2.1.4 Pfizer Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.1.5 Pfizer Recent Developments and Future Plans
    2.2 Fresenius
        2.2.1 Fresenius Details
        2.2.2 Fresenius Major Business
        2.2.3 Fresenius Neuromyelitis Optica Drug Product and Solutions
        2.2.4 Fresenius Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.2.5 Fresenius Recent Developments and Future Plans
    2.3 Teva
        2.3.1 Teva Details
        2.3.2 Teva Major Business
        2.3.3 Teva Neuromyelitis Optica Drug Product and Solutions
        2.3.4 Teva Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.3.5 Teva Recent Developments and Future Plans
    2.4 Sandoz
        2.4.1 Sandoz Details
        2.4.2 Sandoz Major Business
        2.4.3 Sandoz Neuromyelitis Optica Drug Product and Solutions
        2.4.4 Sandoz Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.4.5 Sandoz Recent Developments and Future Plans
    2.5 Intas
        2.5.1 Intas Details
        2.5.2 Intas Major Business
        2.5.3 Intas Neuromyelitis Optica Drug Product and Solutions
        2.5.4 Intas Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.5.5 Intas Recent Developments and Future Plans
    2.6 Gyjtrs
        2.6.1 Gyjtrs Details
        2.6.2 Gyjtrs Major Business
        2.6.3 Gyjtrs Neuromyelitis Optica Drug Product and Solutions
        2.6.4 Gyjtrs Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.6.5 Gyjtrs Recent Developments and Future Plans
    2.7 NANG KUANG
        2.7.1 NANG KUANG Details
        2.7.2 NANG KUANG Major Business
        2.7.3 NANG KUANG Neuromyelitis Optica Drug Product and Solutions
        2.7.4 NANG KUANG Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.7.5 NANG KUANG Recent Developments and Future Plans
    2.8 Tianjin Kingyork
        2.8.1 Tianjin Kingyork Details
        2.8.2 Tianjin Kingyork Major Business
        2.8.3 Tianjin Kingyork Neuromyelitis Optica Drug Product and Solutions
        2.8.4 Tianjin Kingyork Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.8.5 Tianjin Kingyork Recent Developments and Future Plans
    2.9 Baxter
        2.9.1 Baxter Details
        2.9.2 Baxter Major Business
        2.9.3 Baxter Neuromyelitis Optica Drug Product and Solutions
        2.9.4 Baxter Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.9.5 Baxter Recent Developments and Future Plans
    2.10 CSL
        2.10.1 CSL Details
        2.10.2 CSL Major Business
        2.10.3 CSL Neuromyelitis Optica Drug Product and Solutions
        2.10.4 CSL Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.10.5 CSL Recent Developments and Future Plans
    2.11 Grifols
        2.11.1 Grifols Details
        2.11.2 Grifols Major Business
        2.11.3 Grifols Neuromyelitis Optica Drug Product and Solutions
        2.11.4 Grifols Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.11.5 Grifols Recent Developments and Future Plans
    2.12 Octapharma
        2.12.1 Octapharma Details
        2.12.2 Octapharma Major Business
        2.12.3 Octapharma Neuromyelitis Optica Drug Product and Solutions
        2.12.4 Octapharma Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.12.5 Octapharma Recent Developments and Future Plans
    2.13 CBOP
        2.13.1 CBOP Details
        2.13.2 CBOP Major Business
        2.13.3 CBOP Neuromyelitis Optica Drug Product and Solutions
        2.13.4 CBOP Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.13.5 CBOP Recent Developments and Future Plans

3 Market Competition, by Players
    3.1 Global Neuromyelitis Optica Drug Revenue and Share by Players (2018-2023)
    3.2 Market Share Analysis (2022)
        3.2.1 Market Share of Neuromyelitis Optica Drug by Company Revenue
        3.2.2 Top 3 Neuromyelitis Optica Drug Players Market Share in 2022
        3.2.3 Top 6 Neuromyelitis Optica Drug Players Market Share in 2022
    3.3 Neuromyelitis Optica Drug Market: Overall Company Footprint Analysis
        3.3.1 Neuromyelitis Optica Drug Market: Region Footprint
        3.3.2 Neuromyelitis Optica Drug Market: Company Product Type Footprint
        3.3.3 Neuromyelitis Optica Drug Market: Company Product Application Footprint
    3.4 New Market Entrants and Barriers to Market Entry
    3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type
    4.1 Global Neuromyelitis Optica Drug Consumption Value and Market Share by Type (2018-2023)
    4.2 Global Neuromyelitis Optica Drug Market Forecast by Type (2024-2029)

5 Market Size Segment by Application
    5.1 Global Neuromyelitis Optica Drug Consumption Value Market Share by Application (2018-2023)
    5.2 Global Neuromyelitis Optica Drug Market Forecast by Application (2024-2029)

6 North America
    6.1 North America Neuromyelitis Optica Drug Consumption Value by Type (2018-2029)
    6.2 North America Neuromyelitis Optica Drug Consumption Value by Application (2018-2029)
    6.3 North America Neuromyelitis Optica Drug Market Size by Country
        6.3.1 North America Neuromyelitis Optica Drug Consumption Value by Country (2018-2029)
        6.3.2 United States Neuromyelitis Optica Drug Market Size and Forecast (2018-2029)
        6.3.3 Canada Neuromyelitis Optica Drug Market Size and Forecast (2018-2029)
        6.3.4 Mexico Neuromyelitis Optica Drug Market Size and Forecast (2018-2029)

7 Europe
    7.1 Europe Neuromyelitis Optica Drug Consumption Value by Type (2018-2029)
    7.2 Europe Neuromyelitis Optica Drug Consumption Value by Application (2018-2029)
    7.3 Europe Neuromyelitis Optica Drug Market Size by Country
        7.3.1 Europe Neuromyelitis Optica Drug Consumption Value by Country (2018-2029)
        7.3.2 Germany Neuromyelitis Optica Drug Market Size and Forecast (2018-2029)
        7.3.3 France Neuromyelitis Optica Drug Market Size and Forecast (2018-2029)
        7.3.4 United Kingdom Neuromyelitis Optica Drug Market Size and Forecast (2018-2029)
        7.3.5 Russia Neuromyelitis Optica Drug Market Size and Forecast (2018-2029)
        7.3.6 Italy Neuromyelitis Optica Drug Market Size and Forecast (2018-2029)

8 Asia-Pacific
    8.1 Asia-Pacific Neuromyelitis Optica Drug Consumption Value by Type (2018-2029)
    8.2 Asia-Pacific Neuromyelitis Optica Drug Consumption Value by Application (2018-2029)
    8.3 Asia-Pacific Neuromyelitis Optica Drug Market Size by Region
        8.3.1 Asia-Pacific Neuromyelitis Optica Drug Consumption Value by Region (2018-2029)
        8.3.2 China Neuromyelitis Optica Drug Market Size and Forecast (2018-2029)
        8.3.3 Japan Neuromyelitis Optica Drug Market Size and Forecast (2018-2029)
        8.3.4 South Korea Neuromyelitis Optica Drug Market Size and Forecast (2018-2029)
        8.3.5 India Neuromyelitis Optica Drug Market Size and Forecast (2018-2029)
        8.3.6 Southeast Asia Neuromyelitis Optica Drug Market Size and Forecast (2018-2029)
        8.3.7 Australia Neuromyelitis Optica Drug Market Size and Forecast (2018-2029)

9 South America
    9.1 South America Neuromyelitis Optica Drug Consumption Value by Type (2018-2029)
    9.2 South America Neuromyelitis Optica Drug Consumption Value by Application (2018-2029)
    9.3 South America Neuromyelitis Optica Drug Market Size by Country
        9.3.1 South America Neuromyelitis Optica Drug Consumption Value by Country (2018-2029)
        9.3.2 Brazil Neuromyelitis Optica Drug Market Size and Forecast (2018-2029)
        9.3.3 Argentina Neuromyelitis Optica Drug Market Size and Forecast (2018-2029)

10 Middle East & Africa
    10.1 Middle East & Africa Neuromyelitis Optica Drug Consumption Value by Type (2018-2029)
    10.2 Middle East & Africa Neuromyelitis Optica Drug Consumption Value by Application (2018-2029)
    10.3 Middle East & Africa Neuromyelitis Optica Drug Market Size by Country
        10.3.1 Middle East & Africa Neuromyelitis Optica Drug Consumption Value by Country (2018-2029)
        10.3.2 Turkey Neuromyelitis Optica Drug Market Size and Forecast (2018-2029)
        10.3.3 Saudi Arabia Neuromyelitis Optica Drug Market Size and Forecast (2018-2029)
        10.3.4 UAE Neuromyelitis Optica Drug Market Size and Forecast (2018-2029)

11 Market Dynamics
    11.1 Neuromyelitis Optica Drug Market Drivers
    11.2 Neuromyelitis Optica Drug Market Restraints
    11.3 Neuromyelitis Optica Drug Trends Analysis
    11.4 Porters Five Forces Analysis
        11.4.1 Threat of New Entrants
        11.4.2 Bargaining Power of Suppliers
        11.4.3 Bargaining Power of Buyers
        11.4.4 Threat of Substitutes
        11.4.5 Competitive Rivalry
    11.5 Influence of COVID-19 and Russia-Ukraine War
        11.5.1 Influence of COVID-19
        11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis
    12.1 Neuromyelitis Optica Drug Industry Chain
    12.2 Neuromyelitis Optica Drug Upstream Analysis
    12.3 Neuromyelitis Optica Drug Midstream Analysis
    12.4 Neuromyelitis Optica Drug Downstream Analysis

13 Research Findings and Conclusion

14 Appendix
    14.1 Methodology
    14.2 Research Process and Data Source
    14.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Neuromyelitis Optica Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Table 2. Global Neuromyelitis Optica Drug Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
    Table 3. Global Neuromyelitis Optica Drug Consumption Value by Region (2018-2023) & (USD Million)
    Table 4. Global Neuromyelitis Optica Drug Consumption Value by Region (2024-2029) & (USD Million)
    Table 5. Pfizer Company Information, Head Office, and Major Competitors
    Table 6. Pfizer Major Business
    Table 7. Pfizer Neuromyelitis Optica Drug Product and Solutions
    Table 8. Pfizer Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 9. Pfizer Recent Developments and Future Plans
    Table 10. Fresenius Company Information, Head Office, and Major Competitors
    Table 11. Fresenius Major Business
    Table 12. Fresenius Neuromyelitis Optica Drug Product and Solutions
    Table 13. Fresenius Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 14. Fresenius Recent Developments and Future Plans
    Table 15. Teva Company Information, Head Office, and Major Competitors
    Table 16. Teva Major Business
    Table 17. Teva Neuromyelitis Optica Drug Product and Solutions
    Table 18. Teva Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 19. Teva Recent Developments and Future Plans
    Table 20. Sandoz Company Information, Head Office, and Major Competitors
    Table 21. Sandoz Major Business
    Table 22. Sandoz Neuromyelitis Optica Drug Product and Solutions
    Table 23. Sandoz Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 24. Sandoz Recent Developments and Future Plans
    Table 25. Intas Company Information, Head Office, and Major Competitors
    Table 26. Intas Major Business
    Table 27. Intas Neuromyelitis Optica Drug Product and Solutions
    Table 28. Intas Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 29. Intas Recent Developments and Future Plans
    Table 30. Gyjtrs Company Information, Head Office, and Major Competitors
    Table 31. Gyjtrs Major Business
    Table 32. Gyjtrs Neuromyelitis Optica Drug Product and Solutions
    Table 33. Gyjtrs Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 34. Gyjtrs Recent Developments and Future Plans
    Table 35. NANG KUANG Company Information, Head Office, and Major Competitors
    Table 36. NANG KUANG Major Business
    Table 37. NANG KUANG Neuromyelitis Optica Drug Product and Solutions
    Table 38. NANG KUANG Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 39. NANG KUANG Recent Developments and Future Plans
    Table 40. Tianjin Kingyork Company Information, Head Office, and Major Competitors
    Table 41. Tianjin Kingyork Major Business
    Table 42. Tianjin Kingyork Neuromyelitis Optica Drug Product and Solutions
    Table 43. Tianjin Kingyork Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 44. Tianjin Kingyork Recent Developments and Future Plans
    Table 45. Baxter Company Information, Head Office, and Major Competitors
    Table 46. Baxter Major Business
    Table 47. Baxter Neuromyelitis Optica Drug Product and Solutions
    Table 48. Baxter Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 49. Baxter Recent Developments and Future Plans
    Table 50. CSL Company Information, Head Office, and Major Competitors
    Table 51. CSL Major Business
    Table 52. CSL Neuromyelitis Optica Drug Product and Solutions
    Table 53. CSL Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 54. CSL Recent Developments and Future Plans
    Table 55. Grifols Company Information, Head Office, and Major Competitors
    Table 56. Grifols Major Business
    Table 57. Grifols Neuromyelitis Optica Drug Product and Solutions
    Table 58. Grifols Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 59. Grifols Recent Developments and Future Plans
    Table 60. Octapharma Company Information, Head Office, and Major Competitors
    Table 61. Octapharma Major Business
    Table 62. Octapharma Neuromyelitis Optica Drug Product and Solutions
    Table 63. Octapharma Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 64. Octapharma Recent Developments and Future Plans
    Table 65. CBOP Company Information, Head Office, and Major Competitors
    Table 66. CBOP Major Business
    Table 67. CBOP Neuromyelitis Optica Drug Product and Solutions
    Table 68. CBOP Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 69. CBOP Recent Developments and Future Plans
    Table 70. Global Neuromyelitis Optica Drug Revenue (USD Million) by Players (2018-2023)
    Table 71. Global Neuromyelitis Optica Drug Revenue Share by Players (2018-2023)
    Table 72. Breakdown of Neuromyelitis Optica Drug by Company Type (Tier 1, Tier 2, and Tier 3)
    Table 73. Market Position of Players in Neuromyelitis Optica Drug, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
    Table 74. Head Office of Key Neuromyelitis Optica Drug Players
    Table 75. Neuromyelitis Optica Drug Market: Company Product Type Footprint
    Table 76. Neuromyelitis Optica Drug Market: Company Product Application Footprint
    Table 77. Neuromyelitis Optica Drug New Market Entrants and Barriers to Market Entry
    Table 78. Neuromyelitis Optica Drug Mergers, Acquisition, Agreements, and Collaborations
    Table 79. Global Neuromyelitis Optica Drug Consumption Value (USD Million) by Type (2018-2023)
    Table 80. Global Neuromyelitis Optica Drug Consumption Value Share by Type (2018-2023)
    Table 81. Global Neuromyelitis Optica Drug Consumption Value Forecast by Type (2024-2029)
    Table 82. Global Neuromyelitis Optica Drug Consumption Value by Application (2018-2023)
    Table 83. Global Neuromyelitis Optica Drug Consumption Value Forecast by Application (2024-2029)
    Table 84. North America Neuromyelitis Optica Drug Consumption Value by Type (2018-2023) & (USD Million)
    Table 85. North America Neuromyelitis Optica Drug Consumption Value by Type (2024-2029) & (USD Million)
    Table 86. North America Neuromyelitis Optica Drug Consumption Value by Application (2018-2023) & (USD Million)
    Table 87. North America Neuromyelitis Optica Drug Consumption Value by Application (2024-2029) & (USD Million)
    Table 88. North America Neuromyelitis Optica Drug Consumption Value by Country (2018-2023) & (USD Million)
    Table 89. North America Neuromyelitis Optica Drug Consumption Value by Country (2024-2029) & (USD Million)
    Table 90. Europe Neuromyelitis Optica Drug Consumption Value by Type (2018-2023) & (USD Million)
    Table 91. Europe Neuromyelitis Optica Drug Consumption Value by Type (2024-2029) & (USD Million)
    Table 92. Europe Neuromyelitis Optica Drug Consumption Value by Application (2018-2023) & (USD Million)
    Table 93. Europe Neuromyelitis Optica Drug Consumption Value by Application (2024-2029) & (USD Million)
    Table 94. Europe Neuromyelitis Optica Drug Consumption Value by Country (2018-2023) & (USD Million)
    Table 95. Europe Neuromyelitis Optica Drug Consumption Value by Country (2024-2029) & (USD Million)
    Table 96. Asia-Pacific Neuromyelitis Optica Drug Consumption Value by Type (2018-2023) & (USD Million)
    Table 97. Asia-Pacific Neuromyelitis Optica Drug Consumption Value by Type (2024-2029) & (USD Million)
    Table 98. Asia-Pacific Neuromyelitis Optica Drug Consumption Value by Application (2018-2023) & (USD Million)
    Table 99. Asia-Pacific Neuromyelitis Optica Drug Consumption Value by Application (2024-2029) & (USD Million)
    Table 100. Asia-Pacific Neuromyelitis Optica Drug Consumption Value by Region (2018-2023) & (USD Million)
    Table 101. Asia-Pacific Neuromyelitis Optica Drug Consumption Value by Region (2024-2029) & (USD Million)
    Table 102. South America Neuromyelitis Optica Drug Consumption Value by Type (2018-2023) & (USD Million)
    Table 103. South America Neuromyelitis Optica Drug Consumption Value by Type (2024-2029) & (USD Million)
    Table 104. South America Neuromyelitis Optica Drug Consumption Value by Application (2018-2023) & (USD Million)
    Table 105. South America Neuromyelitis Optica Drug Consumption Value by Application (2024-2029) & (USD Million)
    Table 106. South America Neuromyelitis Optica Drug Consumption Value by Country (2018-2023) & (USD Million)
    Table 107. South America Neuromyelitis Optica Drug Consumption Value by Country (2024-2029) & (USD Million)
    Table 108. Middle East & Africa Neuromyelitis Optica Drug Consumption Value by Type (2018-2023) & (USD Million)
    Table 109. Middle East & Africa Neuromyelitis Optica Drug Consumption Value by Type (2024-2029) & (USD Million)
    Table 110. Middle East & Africa Neuromyelitis Optica Drug Consumption Value by Application (2018-2023) & (USD Million)
    Table 111. Middle East & Africa Neuromyelitis Optica Drug Consumption Value by Application (2024-2029) & (USD Million)
    Table 112. Middle East & Africa Neuromyelitis Optica Drug Consumption Value by Country (2018-2023) & (USD Million)
    Table 113. Middle East & Africa Neuromyelitis Optica Drug Consumption Value by Country (2024-2029) & (USD Million)
    Table 114. Neuromyelitis Optica Drug Raw Material
    Table 115. Key Suppliers of Neuromyelitis Optica Drug Raw Materials
List of Figures
    Figure 1. Neuromyelitis Optica Drug Picture
    Figure 2. Global Neuromyelitis Optica Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Figure 3. Global Neuromyelitis Optica Drug Consumption Value Market Share by Type in 2022
    Figure 4. Glucocorticoids
    Figure 5. Immunotherapies
    Figure 6. Others
    Figure 7. Global Neuromyelitis Optica Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Figure 8. Neuromyelitis Optica Drug Consumption Value Market Share by Application in 2022
    Figure 9. Acute Attack Picture
    Figure 10. Remission Prophylactic Treatment Picture
    Figure 11. Global Neuromyelitis Optica Drug Consumption Value, (USD Million): 2018 & 2022 & 2029
    Figure 12. Global Neuromyelitis Optica Drug Consumption Value and Forecast (2018-2029) & (USD Million)
    Figure 13. Global Market Neuromyelitis Optica Drug Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
    Figure 14. Global Neuromyelitis Optica Drug Consumption Value Market Share by Region (2018-2029)
    Figure 15. Global Neuromyelitis Optica Drug Consumption Value Market Share by Region in 2022
    Figure 16. North America Neuromyelitis Optica Drug Consumption Value (2018-2029) & (USD Million)
    Figure 17. Europe Neuromyelitis Optica Drug Consumption Value (2018-2029) & (USD Million)
    Figure 18. Asia-Pacific Neuromyelitis Optica Drug Consumption Value (2018-2029) & (USD Million)
    Figure 19. South America Neuromyelitis Optica Drug Consumption Value (2018-2029) & (USD Million)
    Figure 20. Middle East and Africa Neuromyelitis Optica Drug Consumption Value (2018-2029) & (USD Million)
    Figure 21. Global Neuromyelitis Optica Drug Revenue Share by Players in 2022
    Figure 22. Neuromyelitis Optica Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
    Figure 23. Global Top 3 Players Neuromyelitis Optica Drug Market Share in 2022
    Figure 24. Global Top 6 Players Neuromyelitis Optica Drug Market Share in 2022
    Figure 25. Global Neuromyelitis Optica Drug Consumption Value Share by Type (2018-2023)
    Figure 26. Global Neuromyelitis Optica Drug Market Share Forecast by Type (2024-2029)
    Figure 27. Global Neuromyelitis Optica Drug Consumption Value Share by Application (2018-2023)
    Figure 28. Global Neuromyelitis Optica Drug Market Share Forecast by Application (2024-2029)
    Figure 29. North America Neuromyelitis Optica Drug Consumption Value Market Share by Type (2018-2029)
    Figure 30. North America Neuromyelitis Optica Drug Consumption Value Market Share by Application (2018-2029)
    Figure 31. North America Neuromyelitis Optica Drug Consumption Value Market Share by Country (2018-2029)
    Figure 32. United States Neuromyelitis Optica Drug Consumption Value (2018-2029) & (USD Million)
    Figure 33. Canada Neuromyelitis Optica Drug Consumption Value (2018-2029) & (USD Million)
    Figure 34. Mexico Neuromyelitis Optica Drug Consumption Value (2018-2029) & (USD Million)
    Figure 35. Europe Neuromyelitis Optica Drug Consumption Value Market Share by Type (2018-2029)
    Figure 36. Europe Neuromyelitis Optica Drug Consumption Value Market Share by Application (2018-2029)
    Figure 37. Europe Neuromyelitis Optica Drug Consumption Value Market Share by Country (2018-2029)
    Figure 38. Germany Neuromyelitis Optica Drug Consumption Value (2018-2029) & (USD Million)
    Figure 39. France Neuromyelitis Optica Drug Consumption Value (2018-2029) & (USD Million)
    Figure 40. United Kingdom Neuromyelitis Optica Drug Consumption Value (2018-2029) & (USD Million)
    Figure 41. Russia Neuromyelitis Optica Drug Consumption Value (2018-2029) & (USD Million)
    Figure 42. Italy Neuromyelitis Optica Drug Consumption Value (2018-2029) & (USD Million)
    Figure 43. Asia-Pacific Neuromyelitis Optica Drug Consumption Value Market Share by Type (2018-2029)
    Figure 44. Asia-Pacific Neuromyelitis Optica Drug Consumption Value Market Share by Application (2018-2029)
    Figure 45. Asia-Pacific Neuromyelitis Optica Drug Consumption Value Market Share by Region (2018-2029)
    Figure 46. China Neuromyelitis Optica Drug Consumption Value (2018-2029) & (USD Million)
    Figure 47. Japan Neuromyelitis Optica Drug Consumption Value (2018-2029) & (USD Million)
    Figure 48. South Korea Neuromyelitis Optica Drug Consumption Value (2018-2029) & (USD Million)
    Figure 49. India Neuromyelitis Optica Drug Consumption Value (2018-2029) & (USD Million)
    Figure 50. Southeast Asia Neuromyelitis Optica Drug Consumption Value (2018-2029) & (USD Million)
    Figure 51. Australia Neuromyelitis Optica Drug Consumption Value (2018-2029) & (USD Million)
    Figure 52. South America Neuromyelitis Optica Drug Consumption Value Market Share by Type (2018-2029)
    Figure 53. South America Neuromyelitis Optica Drug Consumption Value Market Share by Application (2018-2029)
    Figure 54. South America Neuromyelitis Optica Drug Consumption Value Market Share by Country (2018-2029)
    Figure 55. Brazil Neuromyelitis Optica Drug Consumption Value (2018-2029) & (USD Million)
    Figure 56. Argentina Neuromyelitis Optica Drug Consumption Value (2018-2029) & (USD Million)
    Figure 57. Middle East and Africa Neuromyelitis Optica Drug Consumption Value Market Share by Type (2018-2029)
    Figure 58. Middle East and Africa Neuromyelitis Optica Drug Consumption Value Market Share by Application (2018-2029)
    Figure 59. Middle East and Africa Neuromyelitis Optica Drug Consumption Value Market Share by Country (2018-2029)
    Figure 60. Turkey Neuromyelitis Optica Drug Consumption Value (2018-2029) & (USD Million)
    Figure 61. Saudi Arabia Neuromyelitis Optica Drug Consumption Value (2018-2029) & (USD Million)
    Figure 62. UAE Neuromyelitis Optica Drug Consumption Value (2018-2029) & (USD Million)
    Figure 63. Neuromyelitis Optica Drug Market Drivers
    Figure 64. Neuromyelitis Optica Drug Market Restraints
    Figure 65. Neuromyelitis Optica Drug Market Trends
    Figure 66. Porters Five Forces Analysis
    Figure 67. Manufacturing Cost Structure Analysis of Neuromyelitis Optica Drug in 2022
    Figure 68. Manufacturing Process Analysis of Neuromyelitis Optica Drug
    Figure 69. Neuromyelitis Optica Drug Industrial Chain
    Figure 70. Methodology
    Figure 71. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Related Reports

Global Neuromyelitis Optica Drug Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Global Neuromyelitis Optica Drug Market 2024 by Company, Regions, Type and Application, Forecast to 2030

date 02 Jan 2024

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global Neuromyelitis Optica Drug market size was valued at USD 48 million in 2023 and is forecast to a readjusted size of USD 59 million by 2030 with a CAGR of 2.9% during review period.

Global Neuromyelitis Optica Drug Supply, Demand and Key Producers, 2024-2030

Global Neuromyelitis Optica Drug Supply, Demand and Key Producers, 2024-2030

date 10 Feb 2024

date Pharma & Healthcare

The global Neuromyelitis Optica Drug market size is expected to reach $ 59 million by 2030, rising at a market growth of 2.9% CAGR during the forecast period (2024-2030).

Product Tags

Neuromyelitis Optica Drug

GABA Supplements

L-carnitine Capsule

Opical Thrombin

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>